Last reviewed · How we verify
primary hyperoxaluria type 1
Approved treatments
- Rivfloza · Novo
Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production. - Rivfloza · Novo
Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- primary hyperoxaluria type 1 patent landscape — cliff calendar, originator estates, attackable patents
- primary hyperoxaluria type 1 treatment landscape brief
- primary hyperoxaluria type 1 treatment updates RSS
Frequently asked questions about primary hyperoxaluria type 1
What drugs treat primary hyperoxaluria type 1?
Tracked treatments include Rivfloza.
What is the treatment for primary hyperoxaluria type 1?
Standard treatment for primary hyperoxaluria type 1 includes Rivfloza. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: primary hyperoxaluria type 1 patent cliff · primary hyperoxaluria type 1 CI report
- Treatment: Rivfloza · Novo
- Treatment: Rivfloza · Novo
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing